Treatment methods with krasg12c inhibition

Abstract

Provided herein are methods of treating diseases including cancers, where the methods comprise administration of Compound 1, or a pharmaceutically acceptable salt thereof, as described herein. Such methods include the treatment of lung cancer comprising a KRASG12C mutation.